[Clinical research of patients with acute or chronic hepatic failure treated with molecular adsorbent recirculating system].
OBJECTIVE
To summarize the experience of a single treatment using molecular adsorbent recirculating system (MARS) in patients with acute-on-chronic liver failure.


METHODS
Twenty-five eases treated by MARS-artificial liver were followed up and reviewed.


RESULTS
The levels of serum total bilirubin, non-conjugated bilirubin and blood ammonia were significantly decreased from (618.51 200.68) mmol/L to (390.81 146.02) mmol/L (t=2.729, P<0.01), (490.03 163.39) mmol/L to (303.28 113.06) mmol/L (t =2.516, P<0.01), and (152.44 82.62)mmol/L to (84.80 13.30)mmol/L (t=2.174, P<0.05), respectively. Prothrombin activity was significantly increased from 70.55% 32.39% to 93.63% 14.20% (t=1.728, P<0.05) in patients during a single 6 h treatment with MARS. No difference was presented in the markers of liver zymogram, serum protein, kidney function, electrolyte, blood routine and blood gas analysis before and after the MARS. Thirteen of 17 patients have been cured or improved, 4 died, and the survival rate was 76.5%.


CONCLUSIONS
MARS is a safe and an effective treatment for patients with liver failure.
Zhou
XinMin
X
Institute of Digestive Diseases, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Wang
Xin
X
Yang
Yan
Y
Zhao
Lin
L
Miao
Jiyan
J
Ding
Jie
J
Fan
Daiming
D
D000328:Adult; D000368:Aged; D000641:Ammonia / Q000097:blood; D001663:Bilirubin / Q000097:blood; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007677:Kidney Function Tests; D017114:Liver Failure, Acute / Q000097:blood / Q000628:therapy*; D008111:Liver Function Tests; D019164:Liver, Artificial / Q000009:adverse effects; D008297:Male; D008875:Middle Aged
D000641:Ammonia; D001663:Bilirubin